Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883267 | 0.85 | CYP19A1 (0.47) | SMN1; SMN2HTTGABRA2GABRB2ALDH1A1 | |
| SCHEMBL4890821 | 0.81 | ALDH1A1 (0.37) | CNR2SMN1; SMN2KDM4EHTTALDH1A1 | |
| SCHEMBL5050796 | 0.80 | ALDH1A1 (0.41) | SMN1; SMN2KDM4EHTTALDH1A1HPGD | |
| SCHEMBL4576808 | 0.78 | ALDH1A1 (0.41) | CNR2SMN1; SMN2KDM4EHTTALDH1A1 | |
| SCHEMBL4890027 | 0.75 | ADORA3 (0.43) | SMN1; SMN2HTTALDH1A1HPGDMAPT | |
| SCHEMBL4576362 | 0.73 | CYP19A1 (0.45) | SMN1; SMN2HTTALDH1A1CYP1A2KMT2A | |
| SCHEMBL4893070 | 0.72 | ALDH1A1 (0.41) | SMN1; SMN2KDM4EHTTALDH1A1CYP1A2 | |
| SCHEMBL13325193 | 0.70 | MAPT (0.46) | SMN1; SMN2KDM4EHTTGABRA2GABRB2 | |
| SCHEMBL13325160 | 0.70 | MAPT (0.45) | SMN1; SMN2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL13325188 | 0.69 | KDM4E (0.51) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1968946-A1 | IMIDAZOLES AS GABA-B RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007073299-A1 | IMIDAZOLES AS GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073299-A1 | IMIDAZOLES AS GABA-B RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312305-A1 | Imidazoles as Gaba- B Receptor Modulators | GABRB1, GABBR2, GABRB2 | CNR2 92/4885SMN1; SMN2 1799/4885KDM4E 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.